Acumen Pharmaceuticals prices public offering of 16.8M shares at $7.75/share

Acumen Pharmaceuticals, Inc.

Offering of 16,774,193 shares at $7.75 each; underwriters have 30-day option for up to 2,516,128 additional shares.
Underwriters include BofA Securities, Citigroup Global Markets, and Stifel; closing expected July 21, 2023.
Estimated offering expenses of ~$440,000 excluding underwriting discounts; proceeds for general corporate purposes.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Acumen Pharmaceuticals, Inc. entered into Underwriting Agreement with BofA Securities, Inc., Citigroup Global Markets Inc. and Stifel, Nicolas & Company, Incorporated, as representatives of the several underwriters (effective 2023-07-18).

Action: entry
Agreement: underwriting
Counterparty: BofA Securities, Inc., Citigroup Global Markets Inc. and Stifel, Nicolas & Company, Incorporated, as representatives of the several underwriters
Effective: 2023-07-18

Exact text from the filing

On July 18, 2023, Acumen Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., Citigroup Global Markets Inc. and Stifel, Nicolas & Company, Incorporated, as representatives of the several underwriters (the “Underwriters”), relating to a public offering (the “Offering”) of 16,774,193 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), at a price to the public of $7.75 per share.

View on SEC.gov

154 material agreements filed in the last 30 days. Browse all material agreements →

Acumen Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-190489

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.